Sanofi SA (ADR) (SNY) announced early Wednesday, its decision to partner with US-based, privately held MyoKardia for the development of first-of-their-kind medicinal therapies designed for individuals suffering from genetic heart diseases.
Novo Nordisk A/S (ADR) (NVO) announced yesterday, that its insulin therapy Tresiba, which was in late-stage trials, has proved to be safe and effective for the treatment of type 1 diabetes in children and young adults.
Sanofi SA (ADR) (SNY) announced yesterday, that it has won the approval of the US Food and Drug Administration (FDA) for a label expansion of its meningococcal vaccine Menactra for use as a booster shot.
Sanofi's subsidiary, Genzyme, is working on a Multiple Sclerosis (MS) drug called Lemtrada. Data revealed by the company indicates that the drug has remained effective in patients even after four years of treatment, and has reduced relapse rates as well.
The designation puts Pfizer ahead of Sanofi SA (ADR) (SNY), which is also developing a similar vaccine. While most forms of the disease can be cured with antibiotics, there currently exists no preventive care for this infection.
Sanofi SA (ADR) (SNY) and Regeneron Pharmaceuticals Inc. (REGN) announced over the weekend that their experimental drug Alirocumab significantly cut the level of cholesterol in four trials, indicating that the treatment may prevent heart disease and ...
Boston, MA 08/28/2014 (wallstreetpr) - According to reports, Sanofi SA (ADR) (NYSE:SNY) has got the green light from the Competition Commission of India in regard with its proposed purchase deal of an arm of Apollo.